resulting in local amino acid deprivation. In addition, unlike Arg1, IDO1 is also endowed with nonenzymatic signaling activity in dendritic cells (DCs) (Mondanelli et al., 2017) . In addition to their inherent immunosuppressive activity, MDSCs might amplify regulatory properties of other immune cells, particularly in tumor microenvironments. Although some mechanisms underlying MDSC-macrophage interaction have been established (Ugel et al., 2015) , the cross-talk between MDSCs and DCs is still unclear (Ostrand-Rosenberg et al., 2012) ; to fill this gap, we have developed this protocol and we demonstrated that Arg1 + MDSCs confer to DCs an IDO1-dependent, immunosuppressive phenotype via Arg1 metabolites (i.e., polyamines such as putrescine and spermidine) (Mondanelli et al., 2017) . The
Procedure
A. MDSCs isolation from bone marrow 1. Take the hind limbs from two C57BL/6 mice, cutting the bone extremities.
2. Under a sterile biosafety cabinet, completely remove flesh from the bones. Put the bones in a Petri dish and inject 10 ml of complete RPMI medium (see Recipes) inside each thigh bone using a 10 ml syringe with a 26 G ½ needle, in order to extract the bone marrow.
3. Aspirate and discharge the medium until the bone marrow cells are completely resuspended, using the same initial 10 ml of RPMI.
4. Transfer the bone marrow cells suspension in a 15 ml Falcon tube supplied with a 40 µm cell strainer, then remove the cell strainer and centrifuge (582 x g, 10 min, RT).
5. Discard the supernatant and resuspend cells in 10 ml of fresh complete RPMI. 12. After 7 days, isolate CD11c + DCs from spleens.
B. CD11c + DCs isolation from spleen 1. Before starting, prepare 2 solutions of collagenase; for each spleen prepare 1 ml of each collagenase solution (15 ml of 100 and 15 ml of 400 U/ml) (see Recipes) as described in the Recipes section.
2. Take spleens from 15 C57BL/6 mice.
3. Put the spleens in a Petri dish and inject in each spleen 1 ml of the 100 U/ml collagenase solution (i.e., for 15 spleens, use 15 ml of 100 U/ml collagenase solution) using a 10 ml syringe 5 www.bio-protocol.org/e2558 with a 26 G ½ needle, until the spleen change colour (spleens colour should fade from red to white). Repeat this step twice.
4. Recover the cell suspension and filter it in a 50 ml Falcon tube supplied with a 40 µm cell strainer, already containing 5 ml of complete RPMI. Keep this supernatant at RT.
5. Incubate the spleens with 1 ml/spleen of 400 U/ml collagenase solution for 30 min at 37 °C.
6. Recover the collagenase solution in a 10 ml syringe and homogenize the spleens using a 2 ml syringe plunger.
7. Resuspend the spleens completely until all splenic cells are in solution using the collagenase solution recovered before. Be sure that cells are homogeneously resuspended, then filter the cell suspension through the cell strainer onto the same 50 ml Falcon tube already containing the first cell suspension recovered from spleens treated with 100 U/ml collagenase.
8. Remove the cell strainer and centrifuge (582 x g, 10 min, RT).
9. Discard the supernatant and resuspend the cellular pellet in 15 ml (1 ml/spleen) of a solution composed by 54% of Nycodenz (see Recipes) and 46% of Nycodenz buffer (see Recipes).
Divide the obtained cellular suspension in three 15 ml Falcon tubes (5 ml/tube).
10. Carefully overlay 3 ml of RPMI medium in each tube containing 5 ml of the cell suspension ( Figure 1A ).
11. Centrifuge at 1,811 x g, 15 min, 4 °C without brake.
12. Recover the ring at the interface of the two phases using a Pasteur pipette and transfer the cells into a new 50 ml Falcon tube ( Figure 1B) . 25. Resuspend cells (1.5 x 10 6 cells/ml) in complete RPMI and plate 4 ml/well in a 6-well plate.
Incubate CD11c + cells overnight at 37 °C, 5% CO2. 3. In the meanwhile, incubate MDSCs 1 x 10 6 cells/ml with the appropriate stimulus (i.e., with and without 150 µM Nor-NOHA to inhibit Arg1 enzymatic activity) for 1 h at 37 °C, then recover and centrifuge MDSCs (582 x g, 10 min, RT).
4. Resuspend MDSCs 0.5 x 10 6 cells in 100 µl of complete RPMI.
